Iranian Journal of Psychiatry and Behavioral Sciences

Published by: Kowsar

Prevalence of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) in Methamphetamine Dependence: A Descriptive Study

Vahid Farnia 1 , Seyyed Bagher Mousavi 1 , Faezeh Tatari 1 , Safora Salemi 1 , * , Sanobar Golshani 1 , Mostafa Alikhani 1 , Shima Heydari 2 and Sara Hookari 1
Authors Information
1 Department of Psychiatry, Substance Abuse Prevention Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Psychiatry, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • Iranian Journal of Psychiatry and Behavioral Sciences: December 2018, 12 (4); e61329
  • Published Online: July 21, 2018
  • Article Type: Original Article
  • Received: September 16, 2017
  • Revised: February 11, 2018
  • Accepted: May 11, 2018
  • DOI: 10.5812/ijpbs.61329

To Cite: Farnia V, Mousavi S B, Tatari F, Salemi S, Golshani S, et al. Prevalence of Childhood Attention-Deficit/Hyperactivity Disorder (ADHD) in Methamphetamine Dependence: A Descriptive Study, Iran J Psychiatry Behav Sci. 2018 ; 12(4):e61329. doi: 10.5812/ijpbs.61329.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Yarmohammadi-Vasel M, Farhoudian A, Farhadi MH, Tavakkoli M. [Therapeutic Community Effectiveness on Self-Esteem and Relapse Rate among Drug Users]. Arch Rehabil. 2012;13(1):114-20. Persian.
  • 2. Shariat SV, Elahi A. Symptoms and course of psychosis after methamphetamine abuse: one-year follow-up of a case. Prim Care Companion J Clin Psychiatry. 2010;12(5). doi: 10.4088/PCC.10l00959gry. [PubMed: 21274351]. [PubMed Central: PMC3026004].
  • 3. Alam-Mehrjerdi Z, Abdollahi M, Higgs P, Dolan K. Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country. Asian J Psychiatr. 2015;16:78-83. doi: 10.1016/j.ajp.2015.06.002. [PubMed: 26168763].
  • 4. Khajeamiri AR, Faizi M, Sohani F, Baheri T, Kobarfard F. Determination of impurities in illicit methamphetamine samples seized in Iran. Forensic Sci Int. 2012;217(1-3):204-6. doi: 10.1016/j.forsciint.2011.11.005. [PubMed: 22153622].
  • 5. Khazaie H, Jalali A, Jozani Y, Moradi S, Heydarpour F, Khaledi-Paveh B. Comparative study on sleep quality and disorders in opiate and methamphetamine users. Heroin Addict Relat Clin Probl. 2016;18(6):21-8.
  • 6. Hajebi A, Amini H, Kashani L, Sharifi V. Twelve-month course and outcome of methamphetamine-induced psychosis compared with first episode primary psychotic disorders. Early Interv Psychiatry. 2016. doi: 10.1111/eip.12404. [PubMed: 27991722].
  • 7. Farnia V, Shakeri J, Tatari F, Juibari TA, Bajoghli H, Golshani S, et al. Demographic and mental history-related data predicted occurrence of psychosis in metamphetamine users. Psychiatry Res. 2016;240:431-4. doi: 10.1016/j.psychres.2016.04.053. [PubMed: 27172885].
  • 8. Shakeri J, Farnia V, Karimi AR, Tatari F, Juibari TA, Alikhani M, et al. The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder. Drug Alcohol Depend. 2016;160:157-62. doi: 10.1016/j.drugalcdep.2015.12.034. [PubMed: 26811120].
  • 9. Heydari ST, Vossoughi M, Akbarzadeh A, Lankarani KB, Sarikhani Y, Javanmardi K, et al. Prevalence and risk factors of alcohol and substance abuse among motorcycle drivers in Fars province, Iran. Chin J Traumatol. 2016;19(2):79-84. [PubMed: 27140214]. [PubMed Central: PMC4897829].
  • 10. Li P, Yu X, Xie J, Yao X, Liu W, Yao J, et al. Expression of cocaine- and amphetamine-regulated transcript (CART) in hen ovary. Biol Res. 2017;50(1):18. doi: 10.1186/s40659-017-0123-x. [PubMed: 28532517]. [PubMed Central: PMC5440929].
  • 11. Osland S, Hirsch L, Pringsheim T. Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder. BJPsych Open. 2017;3(3):141-6. doi: 10.1192/bjpo.bp.116.004317. [PubMed: 28546869]. [PubMed Central: PMC5437375].
  • 12. Haglund M, Ang A, Mooney L, Gonzales R, Chudzynski J, Cooper CB, et al. Predictors of depression outcomes among abstinent methamphetamine-dependent individuals exposed to an exercise intervention. Am J Addict. 2015;24(3):246-51. doi: 10.1111/ajad.12175. [PubMed: 25907813].
  • 13. Lugoboni F, Levin FR, Pieri MC, Manfredini M, Zamboni L, Somaini L, et al. Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs. Psychiatry Res. 2017;250:210-6. doi: 10.1016/j.psychres.2017.01.052. [PubMed: 28473157]. [PubMed Central: PMC5518312].
  • 14. Egan TE, Dawson AE, Wymbs BT. Substance Use in Undergraduate Students With Histories of Attention-Deficit/Hyperactivity Disorder (ADHD): The Role of Impulsivity. Subst Use Misuse. 2017;52(10):1375-86. doi: 10.1080/10826084.2017.1281309. [PubMed: 28406351].
  • 15. Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend. 1998;52(1):15-25. [PubMed: 9788002].
  • 16. Heiligenstein E, Guenther G, Levy A, Savino F, Fulwiler J. Psychological and academic functioning in college students with attention deficit hyperactivity disorder. J Am Coll Health. 1999;47(4):181-5. doi: 10.1080/07448489909595644. [PubMed: 9919849].
  • 17. Kessler RC, Adler LA, Barkley R, Biederman J, Conners CK, Faraone SV, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biol Psychiatry. 2005;57(11):1442-51. doi: 10.1016/j.biopsych.2005.04.001. [PubMed: 15950019]. [PubMed Central: PMC2847347].
  • 18. Sadock BJ, Sadock VA. Synopsis of psychiatry. Philadelphia: Lippincott Williams and Wilkins; 2003.
  • 19. Ernst M, Grant SJ, London ED, Contoreggi CS, Kimes AS, Spurgeon L. Decision making in adolescents with behavior disorders and adults with substance abuse. Am J Psychiatry. 2003;160(1):33-40. doi: 10.1176/appi.ajp.160.1.33. [PubMed: 12505799].
  • 20. Durmus FB, Arman AR, Ayaz AB. Chronotype and its relationship with sleep disorders in children with attention deficit hyperactivity disorder. Chronobiol Int. 2017;34(7):886-94. doi: 10.1080/07420528.2017.1329207. [PubMed: 28574288].
  • 21. Reale L, Bartoli B, Cartabia M, Zanetti M, Costantino MA, Canevini MP, et al. Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry. 2017;26(12):1443-57. doi: 10.1007/s00787-017-1005-z. [PubMed: 28527021].
  • 22. McCann BS, Scheele L, Ward N, Roy-Byrne P. Discriminant validity of the Wender Utah Rating Scale for attention-deficit/hyperactivity disorder in adults. J Neuropsychiatry Clin Neurosci. 2000;12(2):240-5. doi: 10.1176/jnp.12.2.240. [PubMed: 11001603].
  • 23. Mokhtari H, Rabiei M, Salimi SH. Psychometric properties of the persian version of adult attention-deficit/hyperactivity disorder self-report scale. Iran J Psychiatry Clin Psychol. 2015;21(3):244-53.
  • 24. Clure C, Brady KT, Saladin ME, Johnson D, Waid R, Rittenbury M. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am J Drug Alcohol Abuse. 1999;25(3):441-8. [PubMed: 10473007].
  • 25. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol. 2002;30(5):463-75. [PubMed: 12403150].
  • 26. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-65. doi: 10.1017/S003329170500471X. [PubMed: 16420712].
  • 27. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152(11):1652-8. doi: 10.1176/ajp.152.11.1652. [PubMed: 7485630].
  • 28. Biederman J, Wilens TE, Mick E, Faraone SV, Spencer T. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry. 1998;44(4):269-73. [PubMed: 9715358].
  • 29. Biederman J, Wilens T, Mick E, Faraone SV, Weber W, Curtis S, et al. Is ADHD a risk factor for psychoactive substance use disorders? Findings from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1997;36(1):21-9. doi: 10.1097/00004583-199701000-00013. [PubMed: 9000777].
  • 30. Sadeghi Movahed F, Molavi P, Samadzadeh M, Shahbazzadegan B, Askari Moghadam R. [Prevalence of ADHD among the Students Residing in Dormitory of Ardabil University of Medical Sciences]. J Ardabil Univ Med Sci. 2012;12(5):87-94. Persian.
  • 31. Arabgol FHM, Hadid M. Prevalence of attention-deficit/hyperactivity disorder in a group of students. New Cogn Sci. 2004;6(1,2):73-8.
  • 32. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-85. [PubMed: 12509574].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments